Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis

Bone

Volumn 26, Issue 5, 2000, Pages 475-483

  Juraschek, M ^a   Seibel, M J ^a   Woitge, H W ^a   Krempien, B ^a   Bauss, F ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Histomorphometry; Hypercalcemia of malignancy; Ibandronate; Osteoclasts; Pyridinium cross links; Tumor osteopathy

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM; DEOXYPYRIDINOLINE; IBANDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE RELATED PROTEIN; PYRIDINOLINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CELL COUNT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; RAT; TRABECULAR BONE; TUMOR; WALKER CARCINOMA; X RAY DIFFRACTION;

ANIMALS; BIOLOGICAL MARKERS; CARCINOMA 256, WALKER; DIPHOSPHONATES; FEMALE; LONGITUDINAL STUDIES; MODELS, BIOLOGICAL; OSTEOLYSIS; PARATHYROID HORMONE-RELATED PROTEIN; PROTEINS; RATS; RATS, WISTAR;

EID: 0034072523     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00259-3     Document Type: Article

References (53)

1. Bauss F., Minne H.W., Sterz H., Weng U., Wesch H., Ziegler R. Comparative bone analysis via inflammation-mediated osteopenia (IMO) in the rat. Calcif Tissue Int. 37:1985;539-546.
2. Body J.J. Metastatic bone disease Clinical and therapeutic aspects . Bone. 13:(Suppl.):1992;S57-S62.
3. Body J.J., Cleeren A., Pot M., Borkowski A. Serum osteocalcin (BGP) in tumor-associated hypercalcemia. J Bone Miner Res. 1:1986;523-527.
4. Body J.J., Delmas P.D. Urinary pyridinium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol. 74:1992;471-475.
5. Coleman R.E., Houston S., James I., Rodger A., Rubens R.D., Leonard R.C., Ford J. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer. 65:1992;766-768.
6. Delmas P.D., Schlemmer A., Gineyts E., Riis B., Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 6:1991;639-644.
7. Delmas P.D., Wilson D.M., Mann K.G., Riggs B.L. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab. 57:1983;1028-1030.
8. Diel I.J., Kaufmann M., Goerner R., Costa S.D., Kaul S., Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer A prognostic factor for distant metastases . J Clin Oncol. 10:1992;1534-1539.
9. Eastell R., Colwell A., Hampton L., Reeve J. Biochemical markers of bone resorption compared with estimates of bone bone resorption from radiotracer kinetic studies in osteoporosis. J Bone Miner Res. 12:1997;59-65.
10. 2MBP-coated bone. Bone Miner. 6:1989;33-43.
11. Gundberg C.M., Hauschka J.B., Lian J.B., Gallop P.M. Osteocalcin Isolation, characterization and detection . Meth Enzymol. 107:1984;515-544.
12. Hefti E., Trechsel U., Rüfenacht H., Fleisch H. Use of dermestid beetles for cleaning bones. Calcif Tissue Int. 31:1980;45-47.
13. Helger R., Rindfrey H., Hilgenfeldt J. Eine Methode zur direkten Bestimmung des Creatinins im Serum und Urin ohne Enteiweissung nach einer spezifischen modifizierten Jaffe-Reaktion. Z Klin Chem Klin Biochem. 12:1974;344-349.
14. Hiraga T., Tanaka S., Yamamoto M., Nakajima T., Ozawa H. Inhibitory effects of bisphosphonate (YM 175) on bone resorption induced by a metastatic bone tumor. Bone. 18:1996;1-7.
15. Huggia F.M. Overview of cancer related hypercalcemia Epidemiology and etiology . Semin Oncol. 17:1990;3-9.
16. Lipton A., Demers L., Daniloff Y., Curley E., Hamilton C., Harvey H., Witters L., Seaman J., Van der Giessen R., Seyedin S. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem. 39:1993;614-618.
17. 3-induced stimulated bone turnover in the mouse. Calcif Tissue Int. 37:1985;268-275.
18. McLaren A.M., Isdale A.H., Whiting P.H., Bird H.A., Robins S.P. Physiological variation in the urinary excretion of pyridinium crosslinks of collagen. Br J Rheumatol. 32:1993;307-312.
19. Merz W.A. Die Streckenmessung an gerichteten Strukturen im Mikroskop und ihre Anwendung zur Bestimmung von Oberflächen-Volumen-Relationen im Knochengewebe. Mikroskopie. 22:1967;132-142.
20. Monier-Faugere M.C., Fiedler R.M., Bauss F., Malluche H.H. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res. 11:1993;1345-1355.
21. Moro L., Gazzarrini C., Crivellari D., Galligioni E., Talamini R., De Bernard B. Biochemical markers for detecting bone metastases in patients with breast cancer. Clin Chem. 39:1993;131-134.
22. Mühlbauer R.C., Bauss F., Schenk R., Janner M., Bosies E., Strein K., Fleisch H. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res. 9:1991;1003-1011.
23. Mundy G.R. Mechanisms of osteolytic bone destruction. Bone. 12:(Suppl. 1):1991;S1-S6.
24. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R. Bone histomorphometry Standardization of nomenclature, symbols and units . J Bone Miner Res. 2:1987;595-610.
25. Paterson A.H.G., Powles T.J., Kanis J.A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 11:1993;59-65.
26. Paterson C.R., Robins S.P., Horobin J.M., Preece P.E., Cuschieri A. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer. 64:1991;884-886.
27. Pecherstorfer M., Seibel M.J., Woitge H.W., Horn E., Ziegler R., Ludwig M. Urinary pyridinium crosslinks in multiple myeloma, MGUS and osteoporosis. Blood. 90:1997;3743-3750.
28. Pecherstorfer M., Schilling T., Janisch S. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med. 34:1993;1039-1044.
29. Pecherstorfer M., Zimmer-Roth I., Schilling T., Woitge H.W., Schmidt H., Baumgartner G., Thiébaud D., Ludwig H., Seibel M.J. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab. 80:1995;97-103.
30. Pratt D.A., Daniloff Y., Duncan A., Robins S.P. Automated analysis of pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem. 207:1992;168-175.
31. Raisz L.G. Mechanisms and regulation of bone resorption by osteoclastic cells. Coe F.L., Favus M.J. Disorders of Bone and Mineral Metabolism. 1991;295-311 Raven, New York.
32. Rankin S. Radiology. Rubens R.D., Fogelman I. Bone Metastasis. Diagnosis and Treatment. 1991;63-82 Springer, London.
33. Rankin W., Grill V., Martin T.J. Parathyroid-related protein and hypercalcemia. Cancer. 80:(Suppl. 8):1997;1564-1571.
34. Rizzoli R., Caverzasio J., Bauss F., Bonjour J.P. Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein. Bone. 13:1992;321-325.
35. Rizzoli R., Fleisch H. The Walker 256/B carcinosarcoma in thyroparathyroidectomized rats A model to evaluate inhibitors of bone resorption . Calcif Tissue Int. 41:1987;202-207.
36. Robins S.P., Duncan A., Wilson N., Evans B.J. Standardization of pyridinium crosslinks, pyridinoline and desoxypyridinoline, for use of biochemical markers of collagen degradation. Clin Chem. 42:1996;1621-1626.
37. Rodan G.A., Fleisch H. Bisphosphonates Mechanisms of action . J Clin Invest. 12:1996;2692-2696.
38. Rodan S.B., Noda M., Wesolowski G., Rosenblatt M., Rodan G.A. Comparison of postreceptor effects of 1-34 human hypercalcemic factor and 1-34 human parathyroid hormone in rat osteosarcoma cells. J Clin Invest. 81:1988;924-927.
39. Sahni M., Guenther H.L., Fleisch H., Collin P., Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 91:1993;2004-2011.
40. Scharla S.H., Minne H.W., Lempert U.G., Krieg P., Rappel S., Maurer E., Grohe U., Ziegler R. Osteolytic activity of Walker carcinosarcoma 256 is due to parathyroid hormone-related protein (PTHrP). Horm Metab Res. 23:1991;66-69.
41. Schenk R.K., Olah A.J., Hermann W. Preparation of calcified tissues for light microscopy. Dickson G.R. Method of Calcified Tissue Preparation. 1984;1-56 Elsevier, Amsterdam.
42. Schilling T., Blind E., Baier R., Sinn H.S., Moallem E., Silver J., Ziegler R., Raue F. Effects of passive immunization against parathyroid hormone-related protein PTHrP is the responsible factor in mediating hypercalcemia in the Walker carcinosarcoma 256 rat model . J Bone Miner Res. 10:1995;7-16.
43. Seibel M.J., Robins S.P., Bilezikian J.P. Urinary pyridinium crosslinks of collagen. Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab. 3:1992;263-270.
44. Smith R., Russel R.G.G., Bishop M. Diphosphonates and Paget's disease of bone. Lancet. i:1971;945-947.
45. Stewart A.F., Vignery A., Silverglate A., Ravin N.D., LiVolsi V., Broadus A.E., Baron R. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy Uncoupling of bone cell activity . J Clin Endocrinol Metab. 55:1982;219-227.
46. Storm T., Thamsborg G., Streiniche T., Genant H.K., Sorensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. J Bone Miner Res. 8:1990;199-208.
47. Tietz N., Rinker W.A.D., Shaw L.M. IFCC method for alkaline phosphatase. J Clin Chem Clin Biochem. 21:1983;731.
48. Torres R., Diaz-Diego E.M., de la Piedra C., Rapado A. Plasma of Walker-256 carcinoma bearing rat contains parathormone related peptide. Horm Metab Res. 24:1992;246-247.
49. Torres R., de la Piedra C., Rapado A. Effects of the (1-34) fragment of synthetic parathyroid hormone-related protein on tartrate-resistant acid phosphatase and alkaline phosphatase and alkaline phosphatase activities, and on osteocalcin synthesis, in cultured fetal rat calvaria. Miner Electrol Metab. 19:1993;64-70.
50. Torres R., de la Piedra C., Rapado A. Osseous and intestinal compartments in the humoral hypercalcemia of malignancy associated to Walker 256 tumor in rats. Oncology. 50:1993;148-152.
51. Waki Y., Miyamoto K., Kasugai S., Ohya K. Osteoporosis-like changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormone-related protein production. Jpn J Cancer Res. 86:1995;470-476.
52. Yamato H., Nagai Y., Inoue D., Ohnishi Y., Ueyama Y., Ohno H., Matsumoto T., Ogata E., Ikeda K. In vivo evidence for progressive activation of parathyroid hormone-related peptide gene transcription with tumor growth and stimulation of osteoblastic bone formation at early stage of humoral hypercalcemia of cancer. J Bone Miner Res. 10:1995;36-44.
53. Yates A.J., Gutierrez G.E., Smolens P. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism. J Clin Invest. 81:1988;932-938.